Epstein Secrets

inancial ■ Government ■ Energy ■ Basic Materials ■ Communications ■ Consumer, Non-cyclical ■ Industrial ■ Utilities Regions • ■ EI/1O11P ■ North America ■ Emerging Markets ■ Other 2 EFTA00615045 Cash Position ( in 000' USD) Bank CCY Original CCY USD HSBC USD 162,052 162,052 HSBC-LIQUI-

pa 59,690 49,352 37,681 (11,671) 0.72% Lafarge 51,470 89,244 69,931 (19,313) 1.34% Statoil Hydro 50,826 56,142 47,107 (9,036) 0.90% Roche 47,760 45,313 38,046 (7,267) 0.73% Caterpillar 39,984 36,013 34,420 (1,593) 0.66% Tesco 39,130 42,479 36,519 (5,960) 0.70% Groupe D

19158 A Date Of Report: 07/23/2016 M Date Collected: 07/20/2016 Time Collected: 08:52 i) Date Received: 07/20/2016 L Time Received: 23:20 C North America Eastern Time C_INICA'_ REPOt: Clinical Abnormalities Suarnary: ;may ra :ortaw ae aoname [ewes. eau ve toots may rot babe aonnat laps muse 'mew tome

f percent FREE PSA may not be pos ible when the value for TOTAL PSA is in the low mammal range. These gu delines are for assays performed using the Roche E602 immunoassay syS em.(8/2015;V8.0) TESTOSTERONE, TOT.,S. TNP 193.0-740.0 ng/dL 296.0 101/27/2016 Test Not Performed: Specimen rejected for t

(Notes: NON FASTING 1 Specimen ID: 102449709 Date Of Report: 01/28/2016 02:32 Date Collected: 01/27/2016 12:37 Date Received: 01/27/2016 23:01 North America Eastern Time CLINICAL REPORT Clinical Abnormalities Summary: (May not contain all abnormal results; narrative results may not have abnormal flags

f percent FREE PSA may not be possible when the value for TOTAL PSA is in the low normal range. These guidelines are for assays performed using the Roche E170 immunoassay system.(02/2012;v5) TESTOSTERONE, TOT.,S. 296.0 193.0-740.0 ng/dL 112.3 LO 10/27/2015 TESTOSTERONE, BIOAVAIL. 183.8 72.0-46

Specimen ID: 105819158 Date Of Report:07/23/2016 Date Collected:07/20/2016 Time Collected: 08:52 Date Received: 07/20/2016 Time Received: 23:20 North America Eastern Time Clinical Abnormalities !Wirnary: Nal no a-vair all etncere lemAs refra ve .esuss rey VI nrie steams sags fiease Mont eine moon ) Creat

ng prostate cancer by need NOTE: Calculation of percent FREE PSA may not be pos TOTAL PSA is in the low normal range. These gu performed using the Roche E6192 immunoassay sys e_ ,.. ...„._ (>or=70 yrs) 64.5% 40.8% 29.7% 15.8% e biopsy ible when the value for elines are for assays m.(8/20

te Of Report:07/23/2016 E 71ST STREET Date Collected: 07/20/2016 NY 1x021 Time Collected: 08:52 Date Received: 07/20/2016 Time Received: 23:20 North America Eastern Time .." CLINICAL REPORT ."- . ,t,,; sfa :41 R , Bilirubin, Urine NEGATIVE NEGATIVE Blood, Urine NEGATIVE NEGATIVE Nitrites Urine

cancer by need :e NOTE: Calculation of percent FREE PSA may not be post TOTAL PSA is in the low normal range. These guidelines performed using the Roche E602 immunoassay sys TESTOSTERONE, TOT.,S. TOP Test Not Pe-formed: Specimen rejected for testing due hemolysis. 193.0.740.0 ng/dL to moderate o

he healthcare industry with a pre-money valuation of less than $500 million. We expect the companies the Fund invests in to be located primarily in North America. $150 million in commitments ("Capital Commitments") from qualified investors; provided that the General Partner reserves the right to form the Fu

9m. In December 2012, the Principals invested Slim at a valuation of 5204m. Other investors in the round included Kleiner Perkins, Google Ventures, Roche and Labcorp. In September 2013, J.P. Morgan and Goldman Sachs led the IPO of Foundation Medicine. As of 240, January 2014, Foundation Medicine had